J&J publishes nipocalimab Phase II HDFN data as Phase III continues enrolment
The Phase II trial of J&J’s nipocalimab met its primary endpoint, with 54% of the pregnant women achieving a live birth at or after 32 weeks gestational age.
08 August 2024
08 August 2024
The Phase II trial of J&J’s nipocalimab met its primary endpoint, with 54% of the pregnant women achieving a live birth at or after 32 weeks gestational age.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.